What’s News in Earnings: How Big Pharma Is Expanding the GLP-1 Market

Key takeaways

Weight loss drugs, especially GLP-1 therapies, are experiencing rapid growth, with oral pills expanding the market.
Novo Nordisk’s Wagovi pill is currently leading in market performance, but Lilly is poised to compete strongly, especially internationally.
Pricing reductions are shaping the future of the market, potentially limiting revenue growth despite high demand.
The autoimmune drug sector remains highly competitive, with companies like AbbVie and J&J fighting for market share, demonstrating resilience and ongoing innovation.
Market dynamics are shifting, with new formulations and aggressive pricing strategies influencing long-term growth prospects.

Summary

The Surge in the Weight Loss Drug Market

The episode highlights the rapid growth of weight loss drugs, emphasizing Eli Lilly's strong results and forecast upgrades driven by consumer demand for GLP-1 injections. Novo Nordisk's new oral Wagovi pill is also off to a robust start, outperforming Lilly's Fildane. The discussion points out that pills are expanding the market, not just replacing injections, and are appealing to those who prefer a pill over an injection. Despite the growth, pricing reductions are posing risks to overall sales and market estimates.

Competitive Dynamics in Pharmaceutical Launches

The discussion compares Novo Nordisk's Wagovi oral pill with Eli Lilly’s Fildane, noting Wagovi's faster and stronger market entry, due to efficacy and brand familiarity advantages. Lilly expects to leverage international promotion and supply advantages to expand its market share. The ongoing competition is hinting at a broader market expansion for weight management drugs.

Future Growth and Pricing Risks in Obesity Drugs

While sales of drugs like Monjaro and Zepbound are expected to continue growing, the episode discusses the recent significant price reductions—from over $1,000 to as low as $149 per month—which could dampen market growth. Some analysts have already begun lowering their market size estimates, with Novo Nordisk predicting a decline in sales this year as companies trade lower prices for higher volumes.

The Autoimmune Market and Competitive Challenges

The episode also covers the autoimmune drug sector, noting that despite J&J's strong entry with new pills and injectables, AbbVie's existing treatments like SkyRizzy and Renvoke continue to perform well. AbbVie has even raised its sales guidance, signaling confidence, though J&J remains a formidable competitor. The market remains highly competitive, with continued innovation and patient demand.

Show notes

Bonus Episode for May 8. Financial results from pharmaceutical companies Eli Lilly, Novo Nordisk, Merck, Bristol Myers Squibb and AbbVie show strong demand continuing for weight-loss drugs and autoimmune treatments. Wall Street Journal pharma reporter Peter Loftus discusses which drugmakers have the upper hand in the race to dominate those markets.

WSJ Heard on the Street columnist David Wainer hosts this special bonus episode of What's News in Earnings, where we dig into companies’ earnings reports and analyst calls to find out what’s going on under the hood of the American economy.

Sign up for the WSJ's free Markets A.M. newsletter.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.